CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed
Drug / intervention
Melphalan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001587
NCT00001587Phase 1Completed
CompareCT.gov

A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver

National Cancer Institute (NCI)·interventional·Posted Dec 10, 2002·Updated Mar 4, 2008

In Brief

A Phase 1 clinical trial evaluating Isolated hepatic portal and arterial perfusion and Melphalan for Liver Neoplasms and Neoplasm Metastasis. Completed, across 1 site.

Detailed Summary

Patients with unresectable primary or metastatic cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) via the portal vein and hepatic artery with escalating dose melphalan. Patients eligible for this protocol are those with non-colorectal histologies and those with colorectal cancer previously treated with intra-arterial FUDR. Hepatic and systemic toxicity, response to treatment, duration of response, and survival will be followed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Neoplasms, Neoplasm Metastasis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 10, 2002
Enrollment StartSep 1, 1997
Study CompletionMar 1, 2001
TodayJul 2, 2026
Posted 23.6 years ago

Interventions

Isolated hepatic portal and arterial perfusionprocedure

Melphalandrug